Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

The Frequency of CA15-3, CA125, CA19-9 in Patients With Hepatitis B and C

Somayeh Yeganeh-Amirkande 1 , Mehdi Assmar 1 , * , Fariborz Mansour-Ghanaei 2 and Amir Mozafari-Noor 3
Authors Information
1 Department of Microbiology, Lahijan Branch, Islamic Azad University, Lahijan, IR Iran
2 Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, IR Iran
3 Department of Microbiology, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: May 28, 2015, 17 (5)
  • Published Online: May 31, 2015
  • Article Type: Research Article
  • Received: February 15, 2014
  • Accepted: March 8, 2014
  • DOI: 10.17795/zjrms959

To Cite: Yeganeh-Amirkande S, Assmar M, Mansour-Ghanaei F, Mozafari-Noor A. The Frequency of CA15-3, CA125, CA19-9 in Patients With Hepatitis B and C, Zahedan J Res Med Sci. 2015 ;17(5):-. doi: 10.17795/zjrms959.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Dennis LK, Eugene B, Stephen H. Harrison' sprinciples of internal medicine. 2004;
  • 2. Cohan N, Zandieh T, Samiei SH. The prevalence and clinical significance hepatitis B and C co- infection. Iran J Sci. 2006; 31(3): 156-9
  • 3. Lok A, McMahon BJ. Practice guidelines committee, American association for the study of liver diseases and chronic hepatitis B. Hepatology. 2001; 34(6): 1225-41
  • 4. Massarat MS, Tahaghoghimehrizi S. Iranian national health survey: a brief report. Arch Iran Med. 2002; 5(2): 73-9
  • 5. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990; 37(2): 663-76[PubMed]
  • 6. Shi J, Su Q, Zhang C, Huang G, Zhu Y. An intelligent decision support algorithm for diagnosis of colorectal cancer through serum tumor markers. Comput Methods Programs Biomed. 2010; 100(2): 97-107[DOI][PubMed]
  • 7. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008; 66(1): 10-20[DOI][PubMed]
  • 8. Motoo Y, Satomura Y, Mouri I, Mouri H, Ohtsubo K, Sakai J, et al. Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers. Dig Dis Sci. 1999; 44(6): 1142-7[PubMed]
  • 9. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 1998; 35: 99-103[PubMed]
  • 10. El Bokl M, Mabrouk S, Adel Abd El-Mageed NA, Helmy Mahmoud N, Shabana SS. Do serum CA 19-9 and CA 125 levels predict the severity of HCV-related liver fibrosis? Egypt Liver J. 2011; 1(1): 33-7[DOI]
  • 11. Kobeisy MA, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol. 2012; 13(2): 49-53[DOI][PubMed]
  • 12. Heydarpour M, Tavakkoli H, Shafiei D, Koleini N, Arjmandpour A. Correlation between the level of the tumor markers with the stage of liver fibrosis in patients with chronic hepatitis and cirrhosis. Isfahan Med Sch J. 2011; 29(155): 1239-46
  • 13. Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc. 2002; 77(6): 538-41[DOI][PubMed]
  • 14. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984; 50(6): 765-9[PubMed]
  • 15. Bertino G, Ardiri AM, Boemi P, Bruno CM, Valenti M, Mazzarino MC, et al. Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. Minerva Gastroenterol Dietol. 2007; 53(4): 305-9[PubMed]
  • 16. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991; 37(8): 1379-83[PubMed]
  • 17. Schoniger-Hekele M, Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci. 2006; 51(2): 338-45[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments